Wegovy treated a serious form of liver disease in a major clinical trial

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England Journal of Medicine. Metabolic dysfunction-associated steatotic liver disease — previously known as nonalcoholic fatty liver disease — affects about 33% of adults in the U.S. About 5% to 7% have a more advanced form of the disease, called metabolic dysfunction-associated steatohepatitis, or MASH. (Another type of liver disease, alcohol-associated liver disease, is caused by drinking.) Both conditions are...